The low P/S ratio of Enanta Pharmaceuticals may be justified...
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
![](https://pubimg-10000538.picsh.myqcloud.com/20220509000001723ec64e8d0f7.png)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment